VivoSeq
Other

Response to Stress

3

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Response to Stress is an early-stage landscape with 3 programs across 3 companies. The most active players are McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Sebela Pharmaceuticals Development LLC. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

PreclinicalS

Sebela Pharmaceuticals Development LLC

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

1

clinical trials

Completed1 · 100%

Clinical Trials

Trial Activity

Effect of Paroxetine on Smokers' Cardiovascular Response to Stress - 1
Completed·UUniversity of Minnesota·N/A·NCT00218439·105 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)